Johnson and Johnson 2015 Annual Report Download - page 5

Download and view the complete annual report

Please find page 5 of the 2015 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 112

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112

Our broad base enables us to:
 $SFBUFBOEBDDFTTHSPXUIPQQPSUVOJUJFT
across multiple sectors of the health
care market.
 #FBTUSBUFHJDQBSUOFSPGDIPJDFGPS
information technology companies and
innovative start-ups that can benefit from
the deep health care expertise Johnson
& Johnson can uniquely provide.
 8PSLXJUIMPDBMHPWFSONFOUTBOEQVCMJD
health organizations, where we are
collaborating more than ever to address
the world’s most pressing health challenges.
 1SPWJEFPVSDVTUPNFSTXJUICSPBEFS
offerings of products, solutions and
partnership opportunities with us, particularly
in large health care systems focused
on attracting patients, improving patient
outcomes and reducing the cost of care.
 $SFBUFQSPEVDUQMBUGPSNTBOETZTUFNT
that cross categories and establish new
sources of innovation through convergent
combination products. We are excited about
the promise of convergent technologies in
categories like lung cancer, vision care,
biosurgery, robotics, obesity and diabetes.
 3FBMJ[FBEWBOUBHFTPGTDBMFUPBDIJFWF
enterprise efficiencies and capabilities
across all sectors. We are targeting as
much as $1 billion in operational savings
by 2018, to support our growth.
Because of its many advantages, our
broad base ultimately helps us deliver
strong, consistent and sustainable financial
performance. And most importantly, it allows
us to create better products, more valuable
services and improve outcomes for patients,
consumers and their families.
OUR FOCUS IS ON MANAGING
FOR THE LONG TERM—BUILDING
ENDURING EQUITY FOR OUR BRANDS
AND BUILDING SHAREHOLDER VALUE
OVER TIME.
Johnson & Johnson has a set of clear
objectives for creating long-term value. We
expect global health care to grow at three
to five percent over the next five years,
and we have an objective to grow our
sales organically at a faster rate than the
market. We also intend to grow our earnings
faster than sales. When we combine these
objectives with our plans to continue
creating value through strategic acquisitions
and partnerships, as well as our strong
dividend yield, we believe the result to
be a compelling basis for long-term total
shareholder return.
Johnson & Johnson also has a rigorous
and disciplined portfolio review program
focused on creating long-term shareholder
value, and this applies to all our businesses.
We regularly review this approach with
our Board of Directors, and we have a
track record of taking decisive actions,
including divestitures and acquisitions,
in order to meet changing industry and
consumer dynamics.
Additionally, our disciplined capital allocation
strategy allows us to capitalize on the
right opportunities to create greater long-
term value for our shareholders, while also
investing in our businesses for the future.
Our capital allocation strategy starts with
paying dividends to our shareholders.
Next, we seek value-creating strategic
$)"*3."/µ4-&55&3***
OUR BROAD
BASE IN HUMAN
HEALTH CARE
EXTENDS
OUR REACH,
CAPABILITIES
& STRATEGIC
ADVANTAGES
FOR PATIENTS,
PROVIDERS &
CONSUMERS
AROUND THE
WORLD.